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LETTERS TO THE EDITOR
Obesity, Weight Reduction
and Survival in Heart Failure
We read with great interest the study by Horwich et al. (1), and
while we generally agree with their intriguing findings alluding to
better survival with higher body mass index (BMI) among patients
with severe systolic heart failure (HF), we strongly object to their
conclusions suggesting that promotion of weight loss “may even be
potentially harmful.”
In a much smaller cohort of patients with moderate systolic HF
who were followed for an average of 19 months (2), we noted that
83 obese patients (BMI 30 kg/m2) had fewer major events
(cardiovascular death or urgent transplantation) than 142 nonobese
patients (10% events vs. 17% events), although this did not quite
meet statistical significance (p  0.10). Event-free survivors had
significantly greater percent body fat (26.4  7.6% vs. 22.6 
6.7%; p  0.02) than those with a major event. When we divided
patients into quartiles of percent body fat, the lowest quartile had
an annual event rate of 11% compared with 5% in those in the
highest quartile (p  0.05), again implying that body composition
may predict prognosis in chronic HF (3), as is also supported by
data from others (4). However, whether this relationship is merely
an association or is causal is subject to debate, and we strongly
suspect the former relationship. It is likely that lower body weight
(e.g., lower BMI or lower % body fat) is associated with a
heightened metabolic state, associated with higher levels of tumor
necrosis factor and other cytokines in the “cardiac cachexia” of
severe HF. Clearly, cachexia and wasting appears to be an
independent risk factor for mortality in HF (5). In this regard,
involuntary weight loss would likely be associated with a bad
prognosis, whereas we doubt that this would also apply to
purposeful weight reduction.
Clearly, obesity has been associated with numerous adverse
effects on hemodynamics and cardiac structure and function,
including eccentric left ventricular hypertrophy (LVH) and systolic
and diastolic abnormalities, as well as a propensity for more
ventricular arrhythmias and sudden cardiac death (6–10). In a
study of 74 morbidly obese patients, Alpert et al. (11) demon-
strated that nearly one-third had clinical evidence of HF, and the
probability of HF increased with increasing duration of morbid
obesity (at 20 and 25 years of obesity duration, the probability of
congestive heart failure was 66% and 93%, respectively). They
demonstrated significant improvements in New York Heart As-
sociation (NYHA) functional class in nearly 90% of patients who
achieved marked weight reduction; these patients also had signif-
icant improvements in systolic and diastolic ventricular function.
Likewise, weight reduction has been shown to significantly reduce
LVH in obese hypertensives (6,7,10) and to be associated with
marked improvements in exercise capacity and coronary risk
factors in patients with coronary artery disease (12).
Finally, we urge caution that a “risk marker” should not be
confused with a “risk factor” and sweeping conclusions not be
entertained. Thus, whereas low serum cholesterol may mark a
metabolically severe state of HF (13), it should not be immediately
assumed that therapeutic interventions to increase cholesterol shall
yield benefits in HF. Although we agree that further research is
needed on this topic, it has been well documented that obesity
takes a “heavy” toll on the body, particularly on the heart. Until
proven otherwise, we believe that purposeful weight reduction
remains a viable therapy in the prevention and treatment of most
cardiovascular disorders, including HF.
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REPLY
We appreciate the interest of Lavie et al. with regard to our recent
analysis of obesity’s role in the prognosis of advanced heart failure
(HF) (1) and the supporting data they have provided from their
own institution (2). Our study has found that obese HF patients
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have similar to improved prognosis compared with normal or
underweight HF patients, and we maintain that weight reduction
as a therapeutic goal needs to be more closely examined in the
population of advanced HF patients.
We concur that the associations observed in our study and in the
other studies in this area prevent making any firm conclusions
regarding lack of benefit or increased risk of weight loss in
overweight and obese patients with HF. We also noted that even
if obesity is not associated with worse HF survival, weight loss may
be desirable if it results in improved functional capacity and
reduced symptoms. Furthermore, we noted that preoperative
obesity may increase morbidity and mortality with heart transplan-
tation, as well as make it more difficult to find a suitable donor.
With regard to mortality, based on the associations observed in
our study and in the absence of clinical trials demonstrating
benefit, we do not believe raising the possibility that weight loss in
patients with established HF may be an ineffective or even
potentially harmful treatment represents a “sweeping” conclusion.
Because there is potential risk to weight-loss therapies, it does not
seem unreasonable to raise the issue regarding what degree of
benefit, if any, could be expected. Severe calorie restriction in
patients with advanced HF has the potential to worsen cardiac
muscle function (3). In addition, fad diets and pharmacologic
weight-loss agents are associated with risk; for example, the
pro-adrenergic weight-loss agent sibutramine may raise heart rate
and blood pressure (4). Although weight loss may be helpful in the
prevention of coronary artery disease and HF, the data to support
a mortality benefit with weight loss in advanced HF patients is
limited. No randomized controlled trials of weight reduction in
HF powered for clinical end points have been conducted to date.
There is clear and compelling evidence from multiple clinical
trials that medical therapies, including beta-blockers, angiotensin-
converting enzyme inhibitors and aldosterone antagonists, improve
symptoms and prolong survival in patients with severe, chronic HF
(5). We maintain that promotion and implementation of therapies
proven to be life-prolonging take precedence over therapies for
which clinical trial evidence is lacking. Based on the available
evidence we disagree with Lavie et al. that weight reduction is a
treatment for HF until proven otherwise. Clinical trials are clearly
needed to provide definitive guidance. Given the public health
implications, we hope the issues we and Lavie and colleagues have
raised will encourage well-designed clinical trials to address this
important issue. In the absence of definite clinical trial evidence,
physicians should carefully weigh both the potential risks and
potential benefits of weight loss in their overweight and obese HF
patients.
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Ischemic Cardiomyopathy: A Historical Note
I enjoyed reading the recent article on a standardized definition of
ischemic cardiomyopathy by Felker et al. (1). However, I was
somewhat surprised by the fact that the investigators did not make
any reference to the origin of the term “ischemic cardiomyopathy.”
It was George Burch and associates (2) who in 1970 coined the
term “ischemic cardiomyopathy,” which was quite provocative as
well as controversial at the time.
Actually, the concept of ischemic cardiomyopathy dated back
one year earlier when Raftery et al. (3) in England suggested a
cause-and-effect relationship between coronary artery disease and
congestive cardiomyopathy. But the term “ischemic cardiomyop-
athy” was introduced and popularized a year later by Burch et al. in
New Orleans (2). They insisted that “The entity, therefore, should
be accepted and recognized in view of the vast similarities to the
other cardiomyopathies” (2). They emphasized that “ischemic
cardiomyopathy is a true cardiomyopathy” (2).
There have been many systems of classification of cardiomyop-
athy ever since its original description by Brigden in 1957 (4). The
World Health Organization (5) in 1981 classified cardiomyopathy
into hypertrophic, dilated and restrictive types. But from a practical
point of view a more useful classification is an etiologic one to
distinguish between ischemic and non-ischemic varieties, because
the prognosis is quite different. As Felker and associates (1)
mentioned, angiographically diagnosed ischemic cardiomyopathy
with heart failure is associated with a shorter survival than is
non-ischemic cardiomyopathy with heart failure.
We are indebted to Burch et al. (2) for their foresight in
introducing and conceptualizing the term “ischemic cardiomyop-
athy” 32 years before its validation by the Duke Databank (1). As
Burch and associates so aptly stated in 1970, “Early recognition of
coronary artery disease is important so that vigorous and prompt
introduction of all measures available can be instituted to improve
the coronary circulation and prevent the development of muscle
damage or ischemic cardiomyopathy” (2).
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